Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab Tesirine + Prednisone + Rituximab + Vincristine
Phase 2RecruitingDevelopment Stage
Double-Expressor Lymphoma
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
May 24, 2023 → Feb 1, 2028
About Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab Tesirine + Prednisone + Rituximab + Vincristine
Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab Tesirine + Prednisone + Rituximab + Vincristine is a phase 2 stage product being developed by ADC Therapeutics for Double-Expressor Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05600686. Target conditions include Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05600686 | Phase 2 | Recruiting |